drugset / Trial / NCT02348632

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

NCT02348632

Phase 3 Completed 645 enrolled Jazz Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.

Timeline

Start
2015-05
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Solriamfetol Small molecule 75 mg
Subject Solriamfetol Small molecule 150 mg
Subject Solriamfetol Small molecule 300 mg